All In Biotech

Drug Trial Radar · NCT07629817

Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

A Multicenter, Open-Label, Randomized Controlled Phase III Clinical Trial Comparing Surgery Versus Radical Chemoradiotherapy (Organ Preservation) in Patients With Thoracic Esophageal Squamous Cell Carcinoma Achieving cCR or cPR Following Neoadjuvant Immunochemotherapy

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,044 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,044

Planned (sponsor's estimate)

Start

Jun 16, 2026

Primary completion

Mar 15, 2032

Study completion Mar 15, 2032

Sponsor

Lead sponsor
Henan Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell carcinoma (ESCC) who achieve a complete or partial clinical response (cCR/cPR) following neoadjuvant immunochemotherapy.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • Toripalimab + Nab-paclitaxel + Platinum-based ChemotherapyDrug

    This is the standard induction therapy administered to all enrolled patients. It consists of the PD-1 inhibitor Toripalimab combined with Nab-paclitaxel

  • Radiation with Concurrent ChemotherapyCombination product

    Chemotherapy administered concurrently with radiotherapy

  • Radical EsophagectomyProcedure

    Standard surgical procedure with lymph node dissection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year Event-Free Survival (EFS) RateTime frame: 3 years after randomization/treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.